Addressing the Caregiver Burden in Hepatic Encephalopathy Management

Opinion
Video

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, highlight the importance of adhering to evidence-based guidelines and utilizing approved medications in the management of hepatic encephalopathy, emphasizing their crucial role in preventing patient relapse within 30 days of hospital discharge.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 3 experts on hepatic encephalopathy
A panel of 3 experts on hepatic encephalopathy
Video 2 - "Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials"
Video 1 - "Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma"
© 2024 MJH Life Sciences

All rights reserved.